Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Mar 14, 2005; 11(10): 1420-1425
Published online Mar 14, 2005. doi: 10.3748/wjg.v11.i10.1420
Published online Mar 14, 2005. doi: 10.3748/wjg.v11.i10.1420
Table 1 Relative cell numbers in different cell-cycle phases after treatment with sirolimus, tacrolimus and the combination of both. The doses used in these experiments were 25 ng/mL for each compound. Results of one representative experiment are shown.
Cell cycle | Sub-G1 | G1 | S | G2/M |
Hep 3B | ||||
Control | 6 | 69 | 10 | 14 |
Sir | 6 | 73 | 10 | 10 |
Tac | 4 | 65 | 17 | 13 |
Sir + Tac | 16 | 63 | 10 | 9 |
SK-Hep 1 | ||||
Control | 1 | 61 | 16 | 22 |
Sir | 2 | 69 | 12 | 16 |
Tac | 2 | 54 | 13 | 20 |
Sir + Tac | 2 | 82 | 8 | 7 |
- Citation: Schumacher G, Oidtmann M, Rueggeberg A, Jacob D, Jonas S, Langrehr JM, Neuhaus R, Bahra M, Neuhaus P. Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth. World J Gastroenterol 2005; 11(10): 1420-1425
- URL: https://www.wjgnet.com/1007-9327/full/v11/i10/1420.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i10.1420